letter
describ
synthesi
antivir
activ
studi
glycyrrhiz
acid
gl
deriv
influenza
viru
mdck
cell
conjug
gl
lamino
acid
methyl
ester
amino
sugar
dgalactos
amin
dramat
chang
activ
activ
compound
gl
conjug
aromat
amino
acid
methyl
ester
phenylalanin
tyrosin
si
sbenzylcystein
si
thu
modif
gl
perspect
rout
search
new
antivir
gl
deriv
potent
antiinfluenza
agent
letter
describ
synthesi
antivir
activ
studi
glycyrrhiz
acid
gl
deriv
influenza
viru
mdck
cell
conjug
gl
lamino
acid
methyl
ester
amino
sugar
dgalactos
amin
dramat
chang
activ
activ
compound
gl
conjug
aromat
amino
acid
methyl
ester
phenylalanin
tyrosin
si
sbenzylcystein
si
thu
modif
gl
perspect
rout
search
new
antivir
gl
deriv
potent
antiinfluenza
agent
elsevi
ltd
right
reserv
search
new
antivir
agent
one
import
task
chemistri
medicin
wide
spread
social
danger
viral
infect
hiv
hepat
b
c
emerg
new
viral
infect
avian
flu
swine
flu
influenza
ebola
fever
etc
pandem
influenza
spanish
flu
claim
million
live
asian
influenza
viru
led
death
million
person
million
person
die
hong
kong
pandem
influenza
appear
novel
strain
influenza
april
swine
flu
caus
case
death
countri
world
health
organ
declar
pandem
influenza
caus
new
strain
identifi
influenza
viru
form
result
tripl
reassort
swine
avian
human
virus
call
influenza
current
two
class
antivir
drug
adamantan
structureamantadin
rimantadin
neuraminidas
inhibitorszanamivirrelenza
glaxowellcomebiota
oseltamivirtamiflu
hoffmanlarochegilead
use
medicin
treatment
influenza
group
compound
drawback
character
viral
resist
appear
numer
chemic
compound
reach
clinic
trial
belong
differ
chemic
class
exhibit
differ
level
antiinfluenza
activ
vitro
vivo
direct
differ
target
viral
life
cycl
present
research
studi
target
search
new
antivir
influenza
viru
high
prioriti
drug
develop
orient
search
new
compound
modif
alreadi
known
compoundslead
prove
antivir
activ
one
modern
innov
approach
search
new
antivir
applic
avail
natur
compound
plant
metabolit
new
mechan
antivir
activ
natur
compound
deriv
promis
new
candid
treatment
viral
bacteri
fungal
infect
glycyrrhiz
acid
gl
major
triterpen
glycosid
isol
glycyrrhiza
glabra
l
licoric
gl
uralensi
fisher
root
lead
natur
glycosid
promis
scaffold
creation
new
antivir
agent
date
gl
princip
plant
deriv
metabolit
suitabl
longterm
treatment
hiv
infect
lead
emerg
drug
resist
prepar
snmc
stronger
neominophagen
co
contain
gl
use
long
term
chemotherapi
viral
hepat
b
c
gl
attract
due
abil
stimul
cinterferon
product
vitro
vivo
low
toxic
ld
mgkg
gl
activ
antivir
agent
vivo
high
dose
caus
side
effect
connect
structur
similar
corticosteroid
may
influenc
watersalt
interchang
intensifi
na
content
retent
reduc
k
content
patient
report
previous
biolog
activ
gl
could
improv
chemic
modif
semisynthet
gl
deriv
found
potent
immun
modul
antivir
agent
sarsassoci
coronaviru
epsteinbarr
viru
antihiv
agent
found
structureact
relationship
studi
gl
deriv
influenza
viru
inhibitor
carri
still
letter
devot
synthesi
antivir
activ
evalu
gl
deriv
analog
influenza
viru
vitro
gl
isol
purifi
gl
uralensi
fisher
root
collect
siberia
describ
previous
puriti
accord
hplc
experiment
detail
given
refer
note
gl
conjug
synthes
condens
glycosid
lamino
acid
methyl
ester
room
temperatur
rt
use
nhydroxybenzotriazol
hobt
hydrochlorid
dec
molar
ratio
yield
target
compound
analyt
spectral
data
compound
similar
receiv
previous
use
hobtn
n
dicyclohexylcarbodiimid
dcc
gl
conjug
free
prepar
activ
ester
method
use
nhydroxysucinimid
hosu
dcc
molar
ratio
reagent
report
previous
target
compound
isol
column
chromatographi
cc
silica
gel
sl
yield
structur
new
compound
confirm
ir
nmr
c
data
signal
free
ppm
c
nmr
ga
analyt
spectral
data
new
compound
given
refer
note
analyt
spectral
data
compound
similar
synthes
compound
contain
free
amino
acid
synthes
previous
use
hosudcc
sbenzyl
bn
cysteineor
n
e
carbobenzoxi
z
lysin
tertbutyl
ester
hydrochlorid
tertbutyl
ester
group
protect
conjug
delet
cf
cooh
dcm
pure
compound
isol
cc
sl
gl
conjug
dgalactos
amin
connect
carbohydr
part
glycosid
conhbond
synthes
describ
stereo
isomer
produc
alkalin
isomer
gl
accord
method
deriv
conjug
methyl
ester
laspart
acid
describ
previous
gl
analog
prepar
reduct
gl
trimethyl
ester
nabh
accord
method
glycosid
reduc
c
group
synthes
reduct
ga
nabh
describ
gl
deriv
analog
evalu
inhibitori
activ
pandem
influenza
viru
mdck
cell
cytotox
compound
evalu
mdck
cell
cell
viabil
assay
number
viabl
cell
evalu
microtetrazolium
test
mtt
ctd
compound
concentr
requir
reduc
cell
viabil
valu
estim
compound
antivir
activ
compound
evalu
quantif
viru
yield
use
endpoint
dilut
method
rimantadin
use
refer
compound
assay
detail
given
refer
note
antivir
activ
test
compound
evalu
abil
decreas
viru
titer
effect
dose
ed
concentr
compound
decreas
viru
product
twofold
compar
control
calcul
select
index
si
calcul
relat
ctd
ed
compound
si
p
consid
activ
result
experi
shown
tabl
seen
data
present
gl
puriti
possess
low
cytotox
high
valu
ctd
show
antivir
activ
pandem
influenza
viru
si
conjug
gl
contain
three
residu
amino
acid
methyl
ester
activ
activ
among
compound
three
residu
phenylalanin
methyl
ester
si
compound
contain
tyrosin
methyl
ester
residu
less
activ
si
modif
glycosid
part
gl
introduct
amino
acid
methyl
ester
residu
chang
cytotox
antivir
activ
gl
deriv
activ
gl
conjug
free
cooh
compound
ec
lm
nine
tyrosin
methyl
ester
residu
carbohydr
part
gl
almost
chang
toxic
potenti
antivir
activ
time
conjug
time
compound
conjug
gl
sbenzylcystein
compound
led
increas
antivir
activ
time
ec
lm
si
compound
wide
si
valu
rimantadin
time
respect
conjug
gl
amino
acid
contain
two
cooh
group
aspart
acid
dimethyl
ester
led
sharp
increas
cytotox
confer
virusinhibit
properti
compound
modif
glycosid
long
chair
diamin
acid
like
zlysin
slightli
increas
antivir
activ
compound
introduct
heterocycl
amino
acid
histidin
compound
almost
influenc
cytotox
potenti
antivir
activ
compar
gl
time
conjug
gl
dgalactos
amin
compound
led
signific
increas
virusinhibit
activ
si
stereo
isomer
time
toxic
cell
cd
natur
glycosid
week
antivir
activ
deriv
aspart
acid
methyl
ester
conjug
cytotox
less
activ
similar
deriv
gl
chang
carbohydr
part
gl
bsoforosid
chang
cytotox
glycosid
reduc
ec
time
rise
antivir
activ
gl
analog
miss
c
group
contain
dien
system
triterpen
part
toxic
time
mdck
cell
natur
glycosid
time
less
valu
ec
antivir
activ
moder
si
thu
accord
structureact
studi
gl
signific
antivir
activ
influenza
viru
two
stereoisom
differ
substanti
toxic
conjug
gl
amino
acid
methyl
ester
amino
sugar
dramat
chang
activ
activ
compound
conjug
gl
introduct
cystein
phenylalanin
moieti
carbohydr
part
ga
appear
effici
term
antivir
activ
relat
influenza
viru
result
correspond
previou
data
concern
antivir
activ
gl
deriv
sarscov
presenc
free
group
import
antivir
activ
ga
conjug
amino
acid
previous
utsunomiya
et
al
demonstr
due
gl
abil
induc
interferonc
exert
strong
protect
activ
model
lethal
influenza
infect
white
mous
infect
high
viru
dose
ld
influenzainfect
human
macrophag
applic
result
dramat
decreas
product
proinflammatori
cytokin
mechan
activ
suppos
link
decreas
membran
fluiditi
necessari
fusion
viral
envelop
cell
membran
cours
viral
life
cycl
result
show
modif
gl
perspect
rout
search
new
antivir
gl
deriv
potent
antiinfluenza
agent
studi
necessari
deciph
exact
mechan
antivir
activ
ga
deriv
